



Our STN: BL 125742/656

**SUPPLEMENT APPROVAL**  
**PMR FULFILLED**  
August 27, 2025

BioNTech Manufacturing GmbH  
Attention: Leslie Sands  
Pfizer, Inc.  
66 Hudson Boulevard East  
New York, NY 10001

Dear Ms. Sands:

We have approved your request received March 18, 2025, to supplement your Biologics License Application (BLA) submitted under section 351(a) of the Public Health Service Act for COVID-19 Vaccine, mRNA (COMIRNATY), manufactured at the Pfizer Manufacturing Belgium NV, Puurs, Belgium (Pfizer, Puurs) and Pharmacia & Upjohn Company LLC, Kalamazoo, Michigan (Pfizer, Kalamazoo) facilities to include:

- 10 mcg drug product (2025-2026 Formula) in the single-dose vial presentation manufactured at the Pfizer, Puurs facility and associated labeling revisions, for use in individuals 5 years through 11 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19; and
- 30 mcg drug product (2025-2026 Formula) in the single-dose prefilled syringe presentation manufactured at the Pfizer, Puurs facility and associated labeling revisions, for use in individuals who are 65 years of age and older, or 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

The review of this supplement was associated with the following National Clinical Trial (NCT) numbers: NCT4816643 and NCT5543616.

## **LABELING**

Under 21 CFR 201.57(c)(18), patient labeling must be referenced in section 17 PATIENT COUNSELING INFORMATION. Patient labeling must be available and may either be reprinted immediately following the full prescribing information of the package insert or accompany the prescription product labeling.

We hereby approve the draft content of labeling: Package Insert and Patient Package Insert submitted under amendment 43, dated August 26, 2025, and the draft carton and container labels submitted under amendment 16, dated July 11, 2025, amendment 18, dated July 16, 2025, and amendment 30, dated August 8, 2025. We acknowledge your communication plan, submitted under amendment 43, dated August 26, 2025,

concerning the unapproved Prescribing Information contained inside the cartons of certain lots of COMIRNATY (2025-2026 Formula).

## **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, please submit the final content of labeling (21 CFR 601.14) in Structured Product Labeling (SPL) format via the FDA automated drug registration and listing system, (eLIST) as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the Package Insert and Patient Package Insert, submitted on August 26, 2025. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

## **CARTON AND CONTAINER LABELS**

Please electronically submit final printed carton and container labels identical to the carton and container labels submitted on July 11, 2025, July 16, 2025, and August 8, 2025, according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications* at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-certain-human-pharmaceutical-product-applications>.

All final labeling should be submitted as Product Correspondence to this BLA STN BL 125742 at the time of use and include implementation information on Form FDA 356h.

## **ADVERTISING AND PROMOTIONAL LABELING**

You may submit two draft copies of the proposed introductory advertising and promotional labeling with Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration  
Center for Biologics Evaluation and Research  
Document Control Center  
10903 New Hampshire Ave.  
WO71–G112  
Silver Spring, MD 20993-0002

You must submit copies of your final advertising and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).

For each pending supplemental application for this BLA that includes proposed revised labeling, please submit an amendment to update the proposed revised labeling with the changes approved today.

### **FULFILLED POSTMARKETING REQUIREMENTS**

This submission fulfills your postmarketing requirements (PMRs) PMR #1 and PMR #3 identified in the August 15, 2025, letter for BLA STN BL 125742/686. The requirements addressed in this submission are as follows:

#### **PMR #1**

Deferred pediatric Study C4591007 to evaluate the safety and effectiveness of COMIRNATY in children 5 years through 11 years of age.

#### **PMR #3**

Deferred pediatric Study C4591048 Substudy E to evaluate the safety and effectiveness of a single dose of COMIRNATY in children 5 through 11 years of age.

We remind you that there are PMRs and PMCs still open. For each postmarketing study subject to the reporting requirements of 21 CFR 601.70, you must describe the status in an annual report on postmarketing studies for this product. Label your annual report as an **Annual Status Report of Postmarketing Requirements/Commitments** and submit it to the FDA each year within 60 calendar days of the anniversary date of the approval of BLA STN BL 125742 until all Requirements and Commitments subject to the reporting requirements of section 506B of the Federal Food, Drug, and Cosmetic Act are fulfilled or released. The status report for each study should include:

- the sequential number for each study;
- information to identify and describe the postmarketing commitment;
- the original schedule for the commitment;
- the status of the commitment (i.e., pending, ongoing, delayed, terminated, or submitted); and,
- an explanation of the status including, for clinical studies, the patient accrual rate (i.e., number enrolled to date and the total planned enrollment).

As described in 21 CFR 601.70(e), we may publicly disclose information regarding these postmarketing studies on our website <https://www.fda.gov/drugs/guidance-compliance-regulatory-information/postmarket-requirements-and-commitments>.

## **PEDIATRIC REQUIREMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We note that you have fulfilled the pediatric study requirement for ages 5 years through 11 years for this application.

## **POSTMARKETING COMMITMENTS SUBJECT TO REPORTING REQUIREMENTS UNDER SECTION 506B**

We acknowledge your written commitments as described in your correspondence of August 26, 2025, as outlined below:

1. Prospectively designed study to evaluate safety and immunogenicity of COMIRNATY (COVID-19 Vaccine, mRNA) (2025-2026 Formula) in participants 65 years of age and older and in participants 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

Final Protocol Submission: August 30, 2025

Study Initiation: September 30, 2025

Interim Results: February 28, 2026

Study Completion Date: July 31, 2026

Final Report Submission: September 30, 2026

2. A randomized, double-blind, placebo-controlled clinical study evaluating the safety and efficacy of a BNT162b2 variant-adapted vaccine in adults 50 years through 64 years of age without high-risk conditions for severe COVID-19.

Final Protocol Submission: September 30, 2025

Study Initiation: November 30, 2025

Interim Results: May 31, 2026

Study Completion Date: July 31, 2026

Final Report Submission: January 31, 2027

Benefit/Risk Assessment Submission: May 31, 2027

3. Prospectively designed study to evaluate safety and immunogenicity of COMIRNATY (COVID-19 Vaccine, mRNA) (2025-2026 Formula) in participants 5 years through 11 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

Final Protocol Submission: August 30, 2025

Study Initiation: September 30, 2025

Interim Results: February 28, 2026

Study Completion Date: July 31, 2026

Final Report Submission: September 30, 2026

4. A prospective, exploratory, placebo-controlled, randomized study to evaluate detection of circulating SARS-COV-2 spike antigen and self-reported symptoms of post-COVID-19 vaccination syndrome or Long COVID symptoms at Month 1, 3, 6, and 12 in vaccine and control arms.

Final Protocol Submission: January 31, 2026

Study Initiation: April 15, 2026

Study Completion Date: April 30, 2027

Final Report Submission: October 31, 2027

Benefit/Risk Assessment Submission: October 31, 2027

Please submit clinical protocols and interim reports to your IND 19736, and cross-reference letters to BLA STN BL 125742 explaining that these protocols and interim reports were submitted to the IND.

If the information in the final study report supports a change in the labeling, the final study report must be submitted as a supplement. Please use the following designators to prominently label all submissions, including supplements, relating to these postmarketing study commitments as appropriate:

- **Postmarketing Commitment – Correspondence Status Update**
- **Postmarketing Commitment – Final Study Report**
- **Supplement contains Postmarketing Commitment Final Study Report**

For each postmarketing study subject to the reporting requirements of 21 CFR 601.70, you must describe the status in an annual report on postmarketing studies for this product. Label your annual report as an **Annual Status Report of Postmarketing Requirements/Commitments** and submit it to the FDA each year within 60 calendar days of the anniversary date of the approval of BLA STN BL 125742 until all requirements and commitments subject to the reporting requirements of section 506B of the Federal Food, Drug, and Cosmetic Act (FDCA) are fulfilled or released. The status report for each study should include:

- the sequential number for each study as shown in this letter;
- information to identify and describe the postmarketing commitment;
- the original schedule for the commitment;
- the status of the commitment (i.e., pending, ongoing, delayed, terminated, or submitted); and,
- an explanation of the status including, for clinical studies, the patient accrual rate (i.e., number enrolled to date and the total planned enrollment).

As described in 21 CFR 601.70(e), we may publicly disclose information regarding these postmarketing studies on our website at <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Post-marketingPhaseIVCommitments/default.htm>.

We will include information contained in the above-referenced supplement in your BLA file.

Sincerely,

David C. Kaslow, MD  
Director, Office of Vaccines Research and Review  
For (b) (6)  
Office of Vaccines Research and Review  
Center for Biologics Evaluation and Research